Lack of effect of cimetidine on lymphocyte subsets in patients infected with human immunodeficiency virus type 1

Clinical Infectious Diseases

Volumn 23, Issue 5, 1996, Pages 1049-1054

  Cohen, C J ^a,b   Hellinger, J A ^a   Day, J ^a   Salitsky, N ^a   Shevitz, A ^a   Zackin, R ^a   DeGruttola, V ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Comm Res Initiative of New England ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CIMETIDINE; HISTAMINE H2 RECEPTOR;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; T LYMPHOCYTE;

EID: 0029985156     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.5.1049     Document Type: Article

References (20)

1. Kumar A. Cimetidine: an immunomodulator. Drug Intelligence and Clinical Pharmacy 1990;24:289-93.
2. Hahm KB, Kim WH, Lee SI, Kang JK, Park IS. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol 1995;30:265-71.
3. Nielson HJ, Svenningsen A, Moesgaard F, et al. Ranitidine improves certain cellular immune responses in asymptomatic HIV-infected individuals. J Acquir Immune Defic Syndr 1991;4:577-84.
4. Rocklin RE. Modulation of cellular-immune responses in vivo and in vitro by histamine receptor-bearing lymphocytes. J Clin Invest 1976;57: 1051-8.
5. White WB, Ballow M. Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia. N Engl J Med 1985;312:198-202.
6. Marshall M, Riley L, Rhoades J, et al. Quantitative effects of coumarin and cimetidine on peripheral blood lymphocytes and natural killer (NK) cells in patients with advanced malignancies [abstract 738]. In: Proceedings of the Annual Meeting on American Cancer Research. American Cancer Research Society: 1987;28:186.
7. Eisenthal A, Monselise J, Zinger R, Adler A. The effect of cimetidine on PEL from healthy donors and melanoma patients: augmentation of T cell responses to TCGF mitogens and alloantigens and of TCGF production. Cancer Immunol Immunother 1986;21:141-7.
8. Badger AM, Young J, Poste G. Reversal of histamine-mediated immunosuppression by structurally diverse histamine type II (H2) receptor antagonists. Int J Immunopharmacol 1984; 6:467-73.
9. Gifford RRM, Tilberg AF. Histamine type-2 receptor antagonist immune modulation II. Cimetidine and ranitidine increase interleukin-2 production, Surgery 1987; 102:242-7.
10. Brockmeyer NH. Kreutzfelder E, Bluhm C, Shen G, Kuwert EK, Ohnhaus EE. Stimulating potency of cimetidine on the immune system in man. Dr J Clin Pharmacol 1986;21:567p.
11. Borgström S, von Eyben FE, Flodgren P., Axelsson B, Sjögren HO. Combination of cimetidine with other drugs for treatment of cancer [letter]. N Engl J Med 1983:308:592.
12. Festen HPM, de Pauw BE, Smeulders J, Wagener DJT. Cimetidine does not influence immunological parameters in man. Clin Immunol Immunopathol 1981;21:33-8.
13. Maguire LC, Roszman TL, Lackey S. Failure of cimetidine as an immunomodulator in cancer patients and normal subjects. South Med J 1985; 78:1078-80.
14. Jorizzo J, Sams WM Jr, Jegasothy BV, Olansky AJ. Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model. Ann Intern Med 1980;92:192-5.
15. Brockmeyer NH, Kreuzfelder E, Merlins L, et al. Immunomodulatory properties of cimetidine in ARC patients. Clin Immunol Immunopathol 1988;48:50-60.
16. DeGruttola V., Beckett, LA, Coombs RW, et al. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. J Infect Dis 1994; 169:713-21.
17. De Guttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex, J Acquir Immune Defic Syndr 1993;6:359-65.
18. + T-lymphocyte measures in the treatment of individuals infected with human immunodeficiency virus type 1: a review for clinical practitioners. Arch Intern Med 1994;154: 1561-73.
19. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8.
20. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-9.